British Society for Skin Care in Immunosuppressed IndividualsOral presentationsBI01 Intralesional triamcinolone acetonide and antiretroviral therapies: a lesser considered drug interaction

Nicole Fagan,Aisling Ryan

DOI: https://doi.org/10.1093/bjd/ljae090.289

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Antiretroviral therapies (ART) have transformed the management of HIV, leading to increased life expectancy. Dermatologists now encounter a substantial number of patients on ART, necessitating awareness of potential drug interactions. While interactions with oral and intravenous medications are well documented, the impact of ART on intralesional triamcinolone acetonide (TA) is less well recognized. A 43-year-old female patient presented with a 10-year history of keloid scarring secondary to a previous minor trauma. She had a history of HIV and was managed on a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. Her most recent viral load was undetectable. On examination she had Fitzpatrick skin type VI. There was a 2 × 1-cm firm, thick, nontender, dumbbell-shaped nodule consistent with a keloid scar on her central chest. Her quality of life was significantly affected due to the cosmetic appearance, itch and pain. She was treated with intralesional TA 40 mg mL−1 at a dose of 0.1 mL per cm2. Shortly after treatment, correspondence was received from her treating infectious diseases team identifying a contraindication between cobicistat and TA due to the risk of iatrogenic Cushing syndrome (ICS) and secondary adrenal insufficiency (SAI). On review, 33 cases of ICS and SAI in patients concurrently treated with TA and ritonavir have been described in the literature. Three cases have been reported in patients on concurrent cobicistat. The method of administration of TA in these reported cases included intra-articular, epidural, intramuscular and intrabursal routes. Only one case was documented in a dermatology journal, emphasizing the need for increased awareness among dermatologists. Importantly, in some of these cases ICS and SAI developed after a single injection. Ritonavir and cobicistat are potent pharmacokinetic enhancers in HIV treatment, inhibiting cytochrome P450 3A4 (CYP3A4) activity. TA is also metabolized through CYP3A4 leading to increased serum cortisol with concomitant administration. A search using the University of Liverpool’s ‘HIV Drug Interactions Checker’ identified 10 regimens in which coadministration of TA injections are contraindicated and 1 potentially significant interaction. While ART and associated medications are typically managed by HIV specialists, prospective identification and avoidance of harmful drug interactions require communication and heightened awareness among clinicians and patients. The risk of ICS and SAI, even with a single injection, underscores the importance of thorough medication documentation and consideration for drug–drug interactions in patients with HIV, even in topical or intralesional routes.

dermatology